Accelerating research

and development of

new antibiotics and

alternatives

The Netherlands Antibiotic Development Platform

The Netherlands Antibiotic Development Platform (NADP) facilitates the collaboration between public and private organisations, to enhance the development of new antibiotics and alternative therapies for infectious diseases in humans and animals.

NADP will identify relevant research groups, institutes and companies involved in chemical, biological, and/or biomedical antibiotic research to forge collaborations through targeted connections and will organise regular meetings with interested parties.

Stay informed on NADP and subscribe to our Update.

NADP Vouchers

An important objective of NADP is to increase R&D productivity related to new antibiotics and alternatives. To promote the accelerated development of promising 'leads', NADP has developed a financing instrument specifically for this purpose: the NADP Vouchers.

These vouchers can be used in various phases of drug development to gain advice and intensive supervision of research projects from independent consultants or CROs that have specific knowledge and expertise pertinent to the pharmaceutical development process and clinical applications.

Latest News

WHO 2020 preclinical antibacterial pipeline data call open

Companies, institutions and individuals are invited to submit data on their products that are in the preclinical pipeline that fulfil the below inclusion criteria. Data submitted should be non-confidential and will be made available publicly on the WHO Global Health R&D Observatory.

Read More...

Identifying potential antibiotic leads is painfully slow, but these researchers identified 5 in only 6 years

ENABLE surpassed their goal of identifying 3 leads for new antibiotics. With several more compounds in the pipeline, the project has been extended.

Read More...

Investor Webinar: 2020 Antimicrobial Resistance (AMR) Benchmark

On 28 and 29 January, the Access to Medicine Foundation will host an investor webinar about the newly published 2020 AMR Benchmark. It will provide investors with an introduction about the materiality of AMR for the pharmaceutical industry and present the results from the most recent independent comparison of how 30 different pharmaceutical companies are responding to rising rates of drug-resistant infections.

Read More...

NADP Partners

Supported by

NADP Partners

Supported by